BRPI0410429A - derivados de azaindol como inibidores do fator xa - Google Patents

derivados de azaindol como inibidores do fator xa

Info

Publication number
BRPI0410429A
BRPI0410429A BRPI0410429-3A BRPI0410429A BRPI0410429A BR PI0410429 A BRPI0410429 A BR PI0410429A BR PI0410429 A BRPI0410429 A BR PI0410429A BR PI0410429 A BRPI0410429 A BR PI0410429A
Authority
BR
Brazil
Prior art keywords
factor
compounds
formula
vila
inhibitors
Prior art date
Application number
BRPI0410429-3A
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
David William Will
Kurt Ritter
Matthias Urmann
Hans Matter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0410429A publication Critical patent/BRPI0410429A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE AZAINDOL COMO INIBIDORES DO FATOR XA". A presente invenção refere-se a compostos da fórmula I: em que R¬ 0¬, R¬ 1¬, R¬ 2¬, R¬ 3¬, Q, V, G e M têm os significados indicados nas reivindicações. Os compostos da fórmula 1 são compostos ativos farmacologicamente valiosos. Eles exibem um forte efeito antitrombótico e são adequados, por exemplo, para a terapia e profilaxia de distúrbios cardiovasculares, tais como doenças tromboembólicas ou restenose. Eles são inibidores reversíveis das enzimas de coagulação sangüínea fator Xa (FXa) e/ou fator Vila (FVIIa), e podem, em geral, ser aplicados em condições nas quais uma atividade indesejada do fator Xa e/ou fator Vila está presente ou para a cura ou prevenção das quais uma inibição do fator Xa e/ou fator Vila é pretendida. A invenção, além disso, refere-se a processos para a preparação de compostos da fórmula I, seu uso, em particular como ingredientes ativos em produtos farmacêuticos e preparações farmacêuticas compreendendo os mesmos.
BRPI0410429-3A 2003-05-19 2004-05-05 derivados de azaindol como inibidores do fator xa BRPI0410429A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors
PCT/EP2004/004754 WO2004101563A1 (en) 2003-05-19 2004-05-05 AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BRPI0410429A true BRPI0410429A (pt) 2006-06-06

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410429-3A BRPI0410429A (pt) 2003-05-19 2004-05-05 derivados de azaindol como inibidores do fator xa

Country Status (25)

Country Link
EP (2) EP1479680A1 (pt)
JP (1) JP4733642B2 (pt)
KR (1) KR20060012636A (pt)
CN (1) CN100347172C (pt)
AR (1) AR045682A1 (pt)
AU (1) AU2004238500B2 (pt)
BR (1) BRPI0410429A (pt)
CA (1) CA2526084A1 (pt)
CL (1) CL2004001079A1 (pt)
CR (1) CR8088A (pt)
EC (1) ECSP056179A (pt)
HK (1) HK1089175A1 (pt)
MA (1) MA27799A1 (pt)
MX (1) MXPA05012156A (pt)
NO (1) NO20055911L (pt)
NZ (1) NZ543669A (pt)
OA (1) OA13169A (pt)
PE (1) PE20050554A1 (pt)
RS (1) RS20050857A (pt)
RU (1) RU2330853C2 (pt)
TN (1) TNSN05296A1 (pt)
TW (1) TW200510411A (pt)
UA (1) UA86767C2 (pt)
WO (1) WO2004101563A1 (pt)
ZA (1) ZA200508150B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1966199B1 (en) * 2005-11-18 2010-10-20 F. Hoffmann-La Roche AG Azaindole-2-carboxamide derivatives
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
MX2015001897A (es) 2012-08-17 2015-05-11 Bayer Cropscience Ag Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas.
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
CN1181091C (zh) 1994-04-26 2004-12-22 西莱克泰德公司 因子Xa抑制剂
WO1999032477A1 (en) * 1997-12-19 1999-07-01 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
BR9814340B1 (pt) * 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
CA2385592C (en) * 1999-09-17 2011-01-11 Bing-Yan Zhu Benzamides and related inhibitors of factor xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2002080853A2 (en) * 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
ATE468339T1 (de) * 2001-12-20 2010-06-15 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
AU2004238500A1 (en) 2004-11-25
MXPA05012156A (es) 2006-08-18
JP2006528214A (ja) 2006-12-14
CN100347172C (zh) 2007-11-07
KR20060012636A (ko) 2006-02-08
AU2004238500B2 (en) 2010-07-22
PE20050554A1 (es) 2005-08-04
TW200510411A (en) 2005-03-16
HK1089175A1 (en) 2006-11-24
CN1791601A (zh) 2006-06-21
NO20055911L (no) 2006-02-10
UA86767C2 (ru) 2009-05-25
AR045682A1 (es) 2005-11-09
OA13169A (en) 2006-12-13
CR8088A (es) 2006-09-22
CA2526084A1 (en) 2004-11-25
RU2330853C2 (ru) 2008-08-10
RU2005139557A (ru) 2007-06-27
CL2004001079A1 (es) 2005-04-08
NZ543669A (en) 2008-12-24
EP1636226B1 (en) 2014-10-15
TNSN05296A1 (en) 2007-07-10
MA27799A1 (fr) 2006-03-01
RS20050857A (en) 2007-11-15
JP4733642B2 (ja) 2011-07-27
ZA200508150B (en) 2007-02-28
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22
EP1479680A1 (en) 2004-11-24
WO2004101563A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0317659A (pt) Derivados de pirazol como inibidores de fator xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
BRPI0410430A (pt) derivados de indazol como inibidores de fato xa
BR0111264A (pt) Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
ECSP056178A (es) Derivados de bencimidazol como inhibidores del factor xa
BR0011461A (pt) Inibidores do fator viia
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
ECSP056179A (es) Derivados de azaindol como inhibidores del factor xa
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.